A wave of fresh biomedical research is reshaping how we think about disease prevention and treatment. A team led by Ye Cunqi and Jiang Hong showed that a short‑term, low‑methionine diet can ‘pre‑condition’ kidneys, making them more resilient to injury by boosting glucose use. In a parallel effort, scientists at Shaanxi Normal University created a new drug‑screening platform that focuses on brain support cells (astrocytes), opening fresh avenues for treating a rare autoimmune disorder called NMOSD. Researchers at Central South University demonstrated that starting immunochemotherapy early dramatically extends survival for patients with aggressive tumors, thanks to a stronger CD8+ T‑cell response. Engineers at Jiangnan University designed a chitosan‑based scaffold that helps stem cells repair damaged peripheral nerves, a promising step toward clinical nerve‑regeneration therapies. A single‑cell study of penile squamous‑cell cancer identified a protein marker (SEMA3C) that predicts metastasis, offering a potential diagnostic tool. In cancer immunotherapy, a novel CAR‑T approach targets the tumor’s immune shield rather than the cancer cells themselves, showing success in mouse models of ovarian and lung cancer, while combining CAR‑T with the drug TAK‑981 cured most mice with Burkitt lymphoma. Additional highlights include a fast‑acting HIV vaccine candidate (WIN332) that sparks protective antibodies in just three weeks, discovery that brain‑derived signals fuel glioma growth, a genetic variant (ALDH2 rs671) that heightens clot risk, and early results from a Phase III trial of the KRAS‑G12D inhibitor GFH375 for pancreatic cancer. Together, these studies illustrate a rapid move from lab insights to therapies that could soon benefit patients worldwide.
Read more